Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Theodore Karrison to Head and Neck Neoplasms

This is a "connection" page, showing publications Theodore Karrison has written about Head and Neck Neoplasms.

 
Connection Strength
 
 
 
1.261
 
  1. Kocherginsky M, Cohen EE, Karrison T. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. J Biopharm Stat. 2009; 19(3):524-9.
    View in: PubMed
    Score: 0.214
  2. Nathan CO, Hayes DN, Karrison T, Harismendy O, Flores JM, Moore-Medlin T, Vokes EE, Gutkind JS, Neupane P, Mills G, Sargi Z, Seiwert T, Grilley-Olson J, Day T, Gillison M, Wade JL, Feldman L, Jha G, Kozloff M, O'Leary M, Worden FP, Cohen EEW. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048.
    View in: PubMed
    Score: 0.140
  3. Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, Wade JL, Sleckman BG, Anderson D, Brisson RJ, Karrison T, Stadler WM, Vokes EE. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
    View in: PubMed
    Score: 0.118
  4. Kochanny SE, Worden FP, Adkins DR, Lim DW, Bauman JE, Wagner SA, Brisson RJ, Karrison TG, Stadler WM, Vokes EE, Seiwert TY. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
    View in: PubMed
    Score: 0.116
  5. Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park JH, Gao G, Karrison T, Lingen M, Nakamura Y, Hamamoto R. WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget. 2016 Jul 05; 7(27):42527-42538.
    View in: PubMed
    Score: 0.090
  6. Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
    View in: PubMed
    Score: 0.088
  7. Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
    View in: PubMed
    Score: 0.082
  8. Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EEW, Seiwert TY, Haraf DJ, Vokes EE. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
    View in: PubMed
    Score: 0.080
  9. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
    View in: PubMed
    Score: 0.079
  10. Choong NW, Kozloff M, Taber D, Hu HS, Wade J, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
    View in: PubMed
    Score: 0.056
  11. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
    View in: PubMed
    Score: 0.054
  12. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
    View in: PubMed
    Score: 0.051
  13. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.
    View in: PubMed
    Score: 0.045
  14. Karrison T. Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects. Stat Med. 1996 Jan 30; 15(2):171-82.
    View in: PubMed
    Score: 0.022
  15. Vokes EE, Beckett M, Karrison T, Weichselbaum RR. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology. 1992; 49(6):454-60.
    View in: PubMed
    Score: 0.016
  16. Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J, Ervin TJ. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A. 1986 Apr; 83(8):2684-8.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.